Cost vs. Quality: The Debate on Generic Medic...

Jio Platforms is set to file what could be India's largest-ever IPO. But the story goes far beyond the listing. Senior telecom consultant Kalyan Parbat joins host Anirban Chowdhury to break down what the DRHP really signals. From prepaying debt to funding a sovereign LEO satellit ...  Show more

A revolution is underway in cancer diagnosis. A gene-based test called next-generation sequencing can identify precise mutations in a patient’s DNA, which can then be treated with targeted therapies instead of painful chemotherapy. For an 80-year-old woman with stage 4 lung cance ...  Show more

When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. 

Earlier this year, a ban instituted by ...

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry.

How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 1 ...

The second of two episodes this week, taking a deep dive into the pharmaceutical industry.

Big drug companies have won plaudits for their work producing Covid vaccines within a year of the start of the pandemic. How much money are they making from them? And why are vacci ...

How close are we to finding a cure for cancer? What did the government do wrong - in scientific terms - during the pandemic? Do Labour or the Tories have a proper plan to harness the power of British science? On today’s episode of Leading, Alastair and Rory are joined by Nobel P ...  Show more